Methods for diagnosis of lung cancer

Details Methods for diagnosis of lung cancer Methods for diagnosis of lung cancer

2006-05-23

2006-05-23

Myers, Carla J. (Department: 1634)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C536S023100, C536S023500, C536S024310

Reexamination Certificate

active

07049063

ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

REFERENCES:
patent: 5589579 (1996-12-01), Torczynski et al.
patent: 5705159 (1998-01-01), Irie et al.
patent: 5783422 (1998-07-01), Suminami et al.
patent: 6309857 (2001-10-01), Pauli et al.
patent: 2002/0119463 (2002-08-01), Faris et al.
patent: 19924199 (2000-11-01), None
patent: 0695760 (1996-02-01), None
patent: 1033401 (2000-09-01), None
patent: WO 91/18926 (1991-12-01), None
patent: WO 94/06929 (1994-03-01), None
patent: WO 95/21862 (1995-08-01), None
patent: WO 96/02552 (1996-02-01), None
patent: WO 96/13610 (1996-05-01), None
patent: WO 96/28473 (1996-09-01), None
patent: WO 96/30389 (1996-10-01), None
patent: WO 97/07244 (1997-02-01), None
patent: WO 98/35985 (1998-08-01), None
patent: WO 98/46788 (1998-10-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/38973 (1999-08-01), None
patent: WO 99/44620 (1999-09-01), None
patent: WO 99/47674 (1999-09-01), None
patent: WO 99/54738 (1999-10-01), None
patent: WO 00/12711 (2000-03-01), None
patent: WO 00/61612 (2000-10-01), None
patent: WO 02/10449 (2002-02-01), None
patent: WO 02/14366 (2002-02-01), None
Gruber (Cancer Research (Nov. 1999) 59:5488-5491).
Bustin (DNA and Cell Biology (2001)20:331-338).
FASTDB printout of sequence comparison between SEQ ID NO: 160 and SEQ ID NO: 31 of U.S. Patent No. 6,309,857.
Chen, Shen-Lin et al., “Isolation and characterization of a novel gene expressed in multiple cancers,”Oncogene 12: 741-751, 1996.
Güre, A.O. et al., “Human Lung Cancer Antigens Recognized by Autologous Antibodies: Definition of a Novel cDNA Derived from the Tumor Suppressor,”Cancer Research 58:1034-1041, Mar. 1, 1998.
GenBank Database, Accession No. AAD48397, Aug. 11, 1999.
GenBank Database, Accession No. AB026833, May 26, 1999.
GenBank Database, Accession No. AF114429, Jan. 1, 2000.
GenBank Database, Accession No. AF127980, Aug. 11, 1999.
GenBank Database, Accession No. NM—006536, Aug. 10, 1999.
GenBank Database, Accession No. NP—006527, Aug. 10, 1999.
GenBank Database, Accession No. BAA77810, May 26, 1999.
Genseq Database (Derwent), Accession No. AAB45904, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82881, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82886, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82887, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82890, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82893, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82895, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82896, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82897, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAC82898, Mar. 21, 2001.
Genseq Database (Derwent), Accession No. AAX40511, Jun. 18, 1999.
Genseq Database (Derwent), Accession No. AAY11789, Jun. 18, 1999.
GenBank Accession No. AF043977, Jun. 23, 1999.
GenBank Accession No. U85946, Jul. 30, 1999.
Genseq Accession No. AAZ24653, Dec. 7, 1999.
Gruber et al., “Molecular cloning and transmembrane structure of hCLCA2 from human lung, trachea, and mammary gland,”Am. J. Physiol. 276(Cell Physiol 45):C1261-C1270, 1999.
Guo et al., “Identification and characterization of homologues of the Exocyst component Sec10p,”FEBS Letters 404(2-3):135-139, 1997.
Geneseq Accession No. AAC66035, Feb. 21, 2001.
Geneseq Accession No. AAZ36150, Dec. 7, 1999.
Jolly, D., “Viral vector systems for gene therapy,”Cancer Gene Therapy 1(1):51-64, 1994.
Brass et al., “Translation initiation factor eIF-4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma,”Human Molecular Genetics, 6(1):33-39, 1997.
Database EMBLest17 Accession No. AA340797:EST46165 Fetal kidney IIHomo sapienscDNA 3′end, Apr. 18, 1997.
Database EMBLest17 Accession No. W22264:Human retina cDNATsp-5091-cleaved sublibrarHomo sapienscDNA not directional, May 9, 1006.
Finch et al., “Identification of a cloned sequence activated during multi-stae carcinogenesis in mouse skin,”Carcinogenesis, 12(8):1519-1522, Aug. 1991.
Gerhold and Caskey, “It's the genes! EST access to human genome content,”BioEssays 18(12):973-981, 1996.
Russell and Barton, “Structural features can be unconserved in proteins with similar folds,”J. Mol. Biol. 244:332-350, 1994.
Wells and Peitsch, “The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases,”Journal of Leukocyte Biology 61:545-550, May 1997.
Baldi et al., “Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer,”Clinical Cancer Research 3(10):1691-1697, Oct. 1997.
Database EMBL Nucleotide and Protein Sequence, Accession No. AI468638, Mar. 17, 1999.
Davidson et al., “Lung tumours immunoreactive for parathyroid hormone related peptide:analysis of serum calcium levels and tumour type,”Journal of Pathology 178:398-401, Jan. 1996.
Hara et al., “Characterization of cell phenotype of a novel cDNA library substraction system: expression of CD8α in a mast cell-derived interleukin-4-dependent cell line,”Blood 84(1):189-199, Jul. 1, 1994.
Henderson et al., “Identification of lung tumor antigens for cancer immunotherapy: immunological and molecular approaches,”Immunological Investigation 20(2):87-91, May 2000.
Hogan et al., “The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene,”Cancer Research 58(22):5144-5150, Nov. 15, 1998.
Hu et al., “A small proline-rich protein, spr1: specific marker for squamous lung carcinoma,”Lung Cancer 20:25-30, 1998.
Lelievre et al., Structural properties of chimeric peptides containing a T-cell epitope linked to a fusion peptide and their importance for in vivo induction of cytotoxic T-cell responses,European Journal of Biochemistry 249(3):895-904, 1997.
Marshall and Hodgson, “DNA chips: an array of possibilities,”Nature Biotechnology 16:27-31, Jan. 1998.
Pastor et al., “Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis,”Eur. Respir J. 10(3):603-609, Mar. 1997.
Rammensee et al., “MHC ligands and peptide motifs: first listing,”Immunogenetics 41:178-228, 1995.
Ramsay, G., “DNA chips: state-of-the art,”Nature Biotechnology 1640-44, Jan. 1998.
Ruppert et al., “Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules,”Cell 74:929-937, Sep. 10, 1993.
Skeiky et al., “Cloning, expression and immunological evaluation of two putative secreted serine protease antigens ofMycobacterium tuberculosis”, Infection and Immunity 67(8):3998-4007, Aug. 1999.
Theobald et al., “Targeting p53 as a general tumor antigen,”Proc. Natl. Acad. Sci. USA 92:11993-11997, Dec. 1995.
Visseren et al., “Identification of HLA-A *0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product,”International Journal of Cancer 73(1):125-120, 1997.
Wang et al., “Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA substraction and microarray analysis,”Oncogene 19(12):1519-1528, Mar. 16, 2000.

Affiliated with

Also associated with

Rating

Methods for diagnosis of lung cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosis of lung cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosis of lung cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3605732